According to newly reported research, new COVID booster doses that fight Omicron have resulted in an 81 percent decrease in COVID-19 hospitalisations among Israelis aged 65 and older.
The research conducted by Clalit, Ben-Gurion University of the Negev, and Sapir College has not yet been submitted to a formal peer review.
According to Reuters, the research found an 81% reduction in hospitalisations among elders 65 and older who had received the booster compared to those who had not received the Omicron-adapted shot and had previously received at least two COVID vaccinations.
Researchers looked at 622,701 seniors who fulfilled the criteria for the bivalent booster from the end of September to the middle of December. Of them, 85,314 (or 14%) had already received it.
“Hospitalisation due to Covid-19 occurred in 6 bivalent recipients and 297 participants who did not” receive it, the study said. “Death due to Covid-19 occurred in 1 bivalent recipient and 73 participants who did not.”
86% drop in mortality: Researchers
Despite the country having relatively low death rates, the researchers claimed that the 86% drop in mortality was statistically on the edge, but they still thought it was noteworthy.
“Participants who received the bivalent vaccine had lower hospitalisation and mortality rates due to Covid-19 than non-recipients up to 70 days after vaccination.”
Scientists have been closely monitoring another Omicron subvariant, XBB.1.5, which has been quickly spreading in the United States, while the bivalent vaccination primarily targets the original strain and its BA.4/BA.5 Omicron subvariant.
Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOK, INSTAGRAM, and TWITTER.
